Prestige BioPharma announced positive top-line results from a phase III global clinical trial (Troika) evaluating the efficacy, safety, and pharmacokinetics of biosimilar candidate HD201 to Herceptin (trastuzumab).
Myriad Genetics Inc. announced the publication of results from a large study that demonstrated the Prolaris test can accurately predict the 10-year risk of metastases in men newly diagnosed with localized prostate cancer. The study was published in journal Prostate Cancer and Prostatic Diseases.
The National Comprehensive Cancer Network announced the newly-published NCCN Guidelines for Patients: Bladder Cancer, created with funding through the NCCN Foundation.
A new report finds about one in three cancer survivors (34.6%) reported having chronic pain, representing nearly 5.4 million cancer survivors in the U.S. The report, appearing as a Research Letter in JAMA Oncology, finds one in six survivors (16%), representing about 2.5 million people in the U.S., reported suffering from high impact chronic pain that restricts daily functioning. Those rates are about double the rates in the general population.
The standard of care for women with stage III/IVA endometrial cancer following surgery has been chemotherapy and radiation to prevent recurrence. But in a new finding, radiation combined with chemotherapy did not increase recurrence-free survival in these women.
World Trade Center responders with prostate cancer showed signs that inflammation was activated in the prostate after exposure to dust from the World Trade Center site, possibly causing chronic inflammation that contributed to their cancer, according to a study by Mount Sinai researchers in Molecular Cancer Research in June.
There were more than 16.9 million Americans with a history of cancer on Jan. 1, 2019. The number is projected to reach more than 22.1 million by 2030 based on the growth and aging of the population alone, according to estimates from Cancer Treatment and Survivorship Statistics, 2019.
Researchers at the USC Norris Comprehensive Cancer Center found identifying a metastatic colorectal cancer patient's Consensus Molecular Subtype could help oncologists determine the most effective course of treatment. CMS also had prognostic value, meaning each subgroup was indicative of a patient's overall survival, regardless of therapy.
Study suggests higher triple-negative breast cancer incidence among black women is not generalizable
A new study found substantial variation in the prevalence of triple-negative breast cancer among black women with breast cancer by birthplace in the U.S.
Racial disparities in timely cancer treatment disappeared in states that expanded Medicaid under the Affordable Care Act, according to an analysis of over 30,000 health records led by researchers at Yale Cancer Center. The findings were presented at the American Society of Clinical Oncology 2019 annual meeting.
